The Latest Breaking News from Novartis

Exclusive: Consumer healthcare firm Haleon to cut hundreds of roles in UK and potentially thousands globally

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Highlights from Fortune's dinner in Davos.

It's about delivering on corporate missions in a sustainable way, they said at Davos.

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…

The government claims that supply issues have been tackled, but menopausal women know this is far from the truth, says author Rose George

Biomedical innovation reached a new era during the COVID-19 pandemic as drug development went into overdrive. But the ways that brand companies license their patented drugs grant them market monopoly, preventing other entities from making generics so they can exclusively profit. This significantly limits the reach of lifesaving drugs, especially…

Zolgensma may stop five-year-old Yusuf Polat’s spinal muscular atrophy from progressing, but it costs $2.1m.

Unlike antiviral treatments, researchers say the experimental medication would not attack the virus that causes COVID-19, but target the immune system instead.